Urinary Extracellular Vesicles as Early Indicators of Kidney Health and Dsyfunction
By detecting early biological changes before conventional clinical markers become abnormal, this technology has the potential to enable earlier identification of individuals at risk for chronic kidney disease.
Technology
A major challenge in kidney medicine is the lack of sensitive, non-invasive tools capable of detecting early kidney injury before irreversible damage occurs. Traditional clinical markers, including serum creatinine, estimated glomerular filtration rate (eGFR), and albuminuria, are lagging indicators that often
flag damage after severe, irreversible kidney function decline has already taken place. This delayed detection limits opportunities for early intervention, particularly in older adults who are at increased risk of developing chronic kidney disease (CKD). As a result, healthcare providers and clinical researchers require more sensitive biomarkers to detect early kidney changes before abnormalities appear in routine laboratory tests.
University of Delaware Researchers have developed a diagnostic platform based on urinary extracellular vesicles (uEVs), These particles, released by kidney and unriary tract cells, reflect the biological state of these cells and can provide a non-invasive window into early changes in kidney health. The platform has been successfully applied to characterize age-related changes in kidney biology, correlating uEV concentrations with structural and functional alterations in the kidney.
By detecting early biological changes before conventional clinical markers become abnormal, this technology has the potential to enable earlier identification of individuals at risk for CKD. This diagnostic can be readily integrated into routine clinical evaluations and pharmaceutical clinical trials, providing clinicians and drug developers with a sensitive tool to monitor kidney health and treatment response. Earlier detection and intervention may help slow CKD progression, improve patient outcomes, and reduce long-term healthcare costs.
Benefits
-
Early Detection: Detects early biological changes in kidney health before conventional clinical markers, such as serum creatinine or eGFR, indicate functional decline.
-
Sensitive Biomarker of Kidney Aging: Urinary extracellular vesicles reflect age-related changes in kidney cell biology, providing insight into kidney health at the cellular level.
-
Non-Invasive Assessment: Evaluates kidney health using standard, non-invasive diagnostic procedures.
-
Sensitive and Cell-Specific Biomarker: Urinary extracellular vesicles reflect the biological state of their cells of origin, providing insight into kidney health at the cellular level.
-
Imaging-Validated: uEV profiles are associated with advanced MRI measures of kidney structure and function.
-
Broad Clinical Utility: Designed for integration into routine clinical care, preventive screening, and pharmaceutical research to support earlier detection and monitoring of kidney health.
Applications
-
Early Detection of CKD: Non-invasive urine test to identify early kidney injury before traditional clinical markers indicate disease.
-
Pharmaceutical Drug Development: Serves as a sensitive endpoint marker for pharmaceutical companies to evaluate kidney safety and treatment effectiveness during drug development and clinical trials.
-
Precision Medicine (Nephrology): Uses kidney cell-specific urinary extracellular vesicles (uEVs) to identify where kidney damage is occurring and support personalized treatment decisions.
-
High-Risk Patient Monitoring: Enables earlier detection of kidney injury in people with diabetes, hypertension, cancer receiving potentially nephrotoxic therapies, or kidney transplants.
-
Geriatric Preventive Screening: Integrates into routine health check-ups to monitor age-related changes in kidney health before symptoms develop.
-
Treatment Monitoring and Toxicity Assessment: Tracks patient response to kidney-protective therapies and detects early signs of drug-related kidney injury.